Feature | Proton Therapy | September 09, 2015 | Jeff Zagoudis

Proton Therapy Poised for Growth

This article appeared as an introduction to a Comparison Chart on Proton Therapy in the September 2015 issue.

The current state of proton therapy can be assessed fairly quickly by looking at a map: At the end of 2014, there were 51 proton therapy facilities worldwide, with the United States and Japan accounting for more than half (27) and the rest being scattered around the globe. This suggests there are many cancer patients who may not have easy access to proton therapy — a supposition which turns out to be true, according to Paul-Emmanuel Goethals, co-founder of radiation therapy market analysis firm MEDraysintell. According to their numbers, there were roughly 3.2 million patients treated with radiation therapy last year, and only 14,500 of them received proton therapy.

The reason why proton therapy has yet to have a presence in most of the world is no mystery. Like any new technology, initial costs have been high as the equipment is explored and refined — the average price of constructing a proton therapy center has ranged between $150 and $200 million. Many of these facilities were designed with multiple treatment rooms, requiring a larger radiation source with a bigger gantry system to deliver radiation beams to treatment rooms. 

Pulling together such large amounts of capital is difficult on its own, and, compounding the problem, there has been relatively little clinical evidence to support proton therapy as a superior cancer treatment method. At the same time, it is difficult to amass clinical evidence when so few patients are being treated — a difficult paradox to overcome. 

Despite these challenges, the proton therapy market appears poised to boom, according to Goethals and MEDraysintell. In the 2015 World Proton Therapy report, the company projects the market will achieve a $1 billion value in 2019, with 187 new treatment rooms expected to be built in the next four years. To put it in perspective, Goethals reported that the world market value was $300 million in 2010. “While in the past indications were for a few diagnosed cancers, those cases are increasing,” he said. 

 

View a comparison chart of proton therapy systems at www.itnonline.com/content/proton-therapy-systems. This will require a login, which is free and only takes a minute to complete the form.

 

Compact Systems

While such a sudden, dramatic increase may seem abrupt, many of the factors that can drive this growth are already in place, according to Goethals. The key to bringing down the cost of proton therapy, he said, is reducing the size of the equipment — an effort that several manufacturers have already begun.  

Mevion Medical Systems brought the first compact proton therapy system to market when it received U.S. Food and Drug Administration (FDA) and CE mark approval for the S250 system in 2012. At the center of the compact system is a superconducting synchrocyclotron, which is significantly smaller than the traditional linear accelerator (linac) radiation source. The modular system is designed as a single-room solution, but can be adapted into a multi-room configuration. 

Varian entered the compact proton therapy market in 2014 by releasing a smaller version of its original ProBeam system. The ProBeam Compact offers many of the same benefits of its predecessor, including dynamic peak scanning, allowing the application of radiation from different angles simultaneously for intensity-modulated proton therapy, but its 250 MeV cyclotron is more space-efficient than traditional linacs. 

Ion Beam Applications S.A. (IBA) introduced the ProteusONE compact proton therapy system in 2014. ProteusONE is also a single-room system offering several different delivery methods, including intensity-modulated proton therapy (IMPT) and image-guided proton therapy (IGPT).

 

Image Guidance

IBA and Varian are among those that also offer image guidance capabilities. Utilizing IGPT allows radiation oncologists to track the progress of treatment and more precisely target the radiation dose to avoid damage to surrounding tissue and organs. The first image-guided radiotherapy systems have typically used computed tomography (CT) or X-ray, but often encounter issues with image quality and a need to space out sessions to limit extra radiation dose. 

Last December, IBA became one of the first to implement cone beam CT for proton therapy, which provides 3-D images of the anatomy for greater accuracy. Incorporated into ProteusONE, the first cone beam CT-guided treatment was completed in December. Varian also utilizes cone beam CT for imaging on ProBeam and ProBeam Compact, with the option to switch to more traditional kV X-ray imaging on ProBeam. 

 

Treatment Planning

Smaller systems and image guidance have helped raise the influence of proton therapy, but its central premise of pinpoint radiation delivery is ultimately what distinguishes it from other forms of radiation therapy. That high degree of accuracy would be difficult to achieve without effective treatment planning, and the continuing development of treatment planning systems and software have only helped proton therapy spread further. 

Philips initially introduced its Pinnacle3 treatment planning software for general image-guided radiation therapy, but it released a proton therapy-specific version in August 2013 following FDA approval. The module offers automated contouring and re-planning to quickly adapt treatment on the fly, fast commissioning and even combined proton-photon planning if physicians want to combine proton therapy and conventional radiotherapy. In November 2014, Philips announced a partnership with Mevion that would extend Pinnacle support to the new Hyperscan pencil beam scanning capability (a form of IMPT) of the S250. 

RayStation from RaySearch Laboratories has also been a popular choice among proton treatment centers. Pencil beam scanning also is supported here, providing a higher degree of customization to radiation oncologists. “You can actually stop the radiation before it goes too far into a critical structure,” said Marcio Fagundes, M.D., medical director of the Provision Center for Proton Therapy in Knoxville, Tenn., a RayStation user. “It’s really individualizing how you will distribute the dose.” 

 

Related Proton Therapy Content:

Proton Therapy Slowly Growing

Advanced Planning for Accurate Proton Treatments at the Provision Center for Proton Therapy

WEBINAR: Economics of Establishing a Proton Therapy Center

New Approaches to Radiation Therapy

Related Content

Early diagnosis of cancer is one of the highest-priority problem for the healthcare system, because it is critical for overall treatment success and saving patients' lives. Diffusion-weighted magnetic resonance imaging (DWI) may be used to detect a malignancy in various tissues and organs. It has the advantage of providing insight into the diffusion of water molecules in body tissues without exposing patients to radiation.

DWI of the phantom with polyvinylpyrrolidone (PVP) solutions (b value 500 s/mm2). Image courtesy of Kristina Sergunova et al.

News | Magnetic Resonance Imaging (MRI) | June 02, 2020
June 2, 2020 — Early diagnosis of cancer is one of the highest-priority problem for the healthcare system, because it
The FDA has approved Lilly’s TAUVID (flortaucipir F 18 injection), a radioactive diagnostic agent, for PET imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease

Getty Images

News | Contrast Media | June 01, 2020
June 1, 2020 — TAUVID, a radioactive diagnostic agent, has been approved by the FDA for...
MERCK and RefleXion Medical announced a collaboration to evaluate KETRUDA (immunotherapy) with biology-guided radiotherapy - BgRT -  a new radiation machine developed to treat all stages of cancer.

MERCK and RefleXion Medical announced a collaboration to evaluate KETRUDA (immunotherapy) with biology-guided radiotherapy - BgRT -  a new radiation machine developed to treat all stages of cancer.

 

News | Radiation Therapy | June 01, 2020
June 1, 2020 — RefleXion Medical, a therape
Miami Cancer Institute’s Proton Therapy Center is the first in South Florida and the region’s top destination for this leading-edge treatment. Proton therapy is an advanced form of radiation therapy that uses pencil beam scanning (PBS) technology.

Miami Cancer Institute’s Proton Therapy Center is the first in South Florida and the region’s top destination for this leading-edge treatment. Proton therapy is an advanced form of radiation therapy that uses pencil beam scanning (PBS) technology.

Feature | Proton Therapy | May 27, 2020 | By Minesh Mehta, M.D.
Radiation therapy has advanced significantly in the last few decades as a result of a continued technological revolut
Technology becomes a state-of-the-art tool when it gets exposed to a structure that constantly tests it and allows it to evolve.

Technology becomes a state-of-the-art tool when it gets exposed to a structure that constantly tests it and allows it to evolve. Getty Images

Feature | Oncology Information Management Systems (OIMS) | May 27, 2020 | By Reshu Gupta
In the history of medicine, researchers have found cures for many diseases, but cancer has been elusive.
Off-site imaging companies are playing a key role in the fight against COVID-19
Feature | Coronavirus (COVID-19) | May 26, 2020 | By Sean Zahniser
After the worst of the COVID-19 pandemic has pas
a Schematic of the system. The entire solid tumour is illuminated from four sides by a four-arm fibre bundle. A cylindrically focused linear array is designed to detect optoacoustic signals from the tumour. In vivo imaging is performed in conical scanning geometry by controlling the rotation and translation stages. The sensing part of the transducer array and the tumour are submerged in water to provide acoustic coupling. b Maximum intensity projections of the optoacoustic reconstruction of a phantom of pol

a Schematic of the system. The entire solid tumour is illuminated from four sides by a four-arm fibre bundle. A cylindrically focused linear array is designed to detect optoacoustic signals from the tumour. In vivo imaging is performed in conical scanning geometry by controlling the rotation and translation stages. The sensing part of the transducer array and the tumour are submerged in water to provide acoustic coupling. b Maximum intensity projections of the optoacoustic reconstruction of a phantom of polyethylene microspheres (diameter, 20 μm) dispersed in agar. The inset shows a zoomed-in view of the region boxed with a yellow dashed line. In addition, the yellow boxes are signal profiles along the xy and z axes across the microsphere centre, as well as the corresponding full width at half-maximum values. c Normalized absorption spectra of Hb, HbO2 and gold nanoparticles (AuNPs). The spectrum for the AuNPs was obtained using a USB4000 spectrometer (Ocean Optics, Dunedin, FL, USA), while the spectra for Hb and HbO2 were taken from http://omlc.org/spectra/haemoglobin/index.html. The vertical dashed lines indicate the five wavelengths used to stimulate the three absorbers: 710, 750, 780, 810 and 850 nm. Optoacoustic signals were filtered into a low-frequency band (red) and high-frequency band (green), which were used to reconstruct separate images.

News | Breast Imaging | May 26, 2020
May 26, 2020 — Breast cancer is the most common cancer in women.
A new technique developed by researchers at UC Davis offers a significant advance in using magnetic resonance imaging to pick out even very small tumors from normal tissue. The team created a probe that generates two magnetic resonance signals that suppress each other until they reach the target, at which point they both increase contrast between the tumor and surrounding tissue

A new technique developed by researchers at UC Davis offers a significant advance in using magnetic resonance imaging to pick out even very small tumors from normal tissue. The team created a probe that generates two magnetic resonance signals that suppress each other until they reach the target, at which point they both increase contrast between the tumor and surrounding tissue. Image courtesy of Xiandoing Xue, UC Davis

News | Magnetic Resonance Imaging (MRI) | May 26, 2020
May 26, 2020 — Researchers at the University of California, Davis offers a...